The Human Retroviruses¶
Chapter 207 | Part 5: Infectious Diseases
KEY CLINICAL POINTS¶
- Retroviruses (Retroviridae) are RNA viruses with unique replication cycles involving reverse transcription and integration into host genomes.
- Human retroviruses include HTLV-1 (causes ATL and HAM) and HIV-1/HIV-2 (causes AIDS), with distinct pathogenic mechanisms and clinical manifestations.
- HTLV-1 transmission occurs via breast milk, sexual contact, and blood transfusions, with ~3% lifetime risk of developing ATL and 4% risk of HAM.
- Retroviral integration can lead to oncogenesis via activation of proto-oncogenes or disruption of tumor suppressor genes.
- Treatment for HTLV-1-associated diseases includes chemotherapy, interferon, and stem cell transplantation, with limited curative options.
1. DEFINITION & OVERVIEW¶
Retroviruses are RNA viruses that replicate via reverse transcription, converting their RNA genome into DNA which integrates into the host genome. They include both exogenous (infectious) and endogenous (germline) forms. Human retroviruses such as HTLV-1 and HIV-1 are critical pathogens with distinct clinical impacts.
Table 207-1 Classification of Retroviruses: The Family Retroviridae¶
| GENUS | EXAMPLE(S) | FEATURE |
|---|---|---|
| Alpharetrovirus | Rous sarcoma virus | Contains src oncogene |
| Betaretrovirus | Mouse mammary tumor virus | Exogenous or endogenous |
| Gammaretrovirus | Abelson murine leukemia virus | Contains abl oncogene |
| Deltaretrovirus | HTLV-1 | Causes T-cell lymphoma and neurologic disease |
| Lentivirus | HIV-1, HIV-2 | Causes AIDS |
| Spumavirus | Simian foamy virus | Not known to be pathogenic in humans |
1.1 Retroviral Structure and Life Cycle¶
Retroviruses are 70–130 nm in diameter with a lipid envelope, containing RNA genome (8–10 kb), reverse transcriptase, and integrase. The life cycle includes attachment, reverse transcription, integration, and viral assembly. Lentiviruses (e.g., HIV) can infect nondividing cells due to Vpr-mediated mechanisms.
1.2 Classification of Retroviruses¶
The family Retroviridae includes seven subfamilies (Table 207-1). Human pathogens include deltaretroviruses (HTLV-1) and lentiviruses (HIV-1/HIV-2). Spumaviruses and epsilonretroviruses are generally nonpathogenic in humans.
2. EPIDEMIOLOGY¶
HTLV-1 is endemic in southwestern Japan, Okinawa, and parts of Africa, the Caribbean, and South America. Global prevalence is estimated at 10–20 million infections. Transmission occurs via breast milk, sexual contact, and blood transfusions. HAM and ATL are rare, with ~500 ATL cases/year in Japan.
2.1 Risk Factors¶
Perinatal transmission, sexual contact, blood transfusions, and immunosuppression increase risk. HTLV-1 is less infectious than HIV due to cell-to-cell transmission requirements.
2.2 Demographics¶
HTLV-1 is more common in women (HAM) and men (ATL). HAM disproportionately affects females, while ATL is more prevalent in perinatally infected individuals.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
HTLV-1 encodes Tax (induces oncogenesis) and HBZ (maintains transformed state). HIV-1 uses Vif to counteract APOBEC3 enzymes. Retroviral integration can disrupt proto-oncogenes (e.g., c-rel, fos/jun) or tumor suppressors, leading to neoplasia or immune dysfunction.
3.1 Oncogenic Mechanisms¶
Tax induces genomic instability via DNA damage, cytokine autocrine loops, and immune evasion. HBZ represses DNA repair enzymes, allowing genetic damage accumulation. Integration near proto-oncogenes (e.g., c-myc) drives transformation.
3.2 Immune Evasion¶
Retroviruses downregulate CD4 (HIV) or MHC molecules, evading immune detection. HTLV-1 Tax interferes with G1/S cell cycle checkpoints and apoptosis.
4. CLINICAL FEATURES¶
HTLV-1 infection may be asymptomatic or progress to ATL (acute, lymphomatous, chronic, smoldering) or HAM (spastic paraparesis). Symptoms include skin lesions, hypercalcemia, CNS involvement, and opportunistic infections.
4.1 Adult T-Cell Leukemia/Lymphoma (ATL)¶
Acute ATL: rapid progression, skin lesions, hypercalcemia, and lymphadenopathy. Chronic ATL: indolent course with normal calcium levels. Lymphomatous ATL: rare, with lymph node involvement. Smoldering ATL: <5% of cases with minimal symptoms.
4.2 Tropical Spastic Paraparesis (HAM)¶
Insidious onset with spastic paraparesis, urinary incontinence, and CNS inflammation. MRI shows white matter lesions. Autoimmune mechanisms may drive neuronal damage via T-cell reactivity to viral antigens.
5. DIFFERENTIAL DIAGNOSIS¶
ATL must be differentiated from other lymphomas (e.g., NHL) and mycosis fungoides. HAM resembles multiple sclerosis but lacks oligoclonal bands in CSF. HTLV-1 infection should be considered in patients with unexplained myelopathy or T-cell lymphoproliferative disorders.
5.1 Non-Retroviral Mimics¶
Multiple sclerosis (HAM mimic), cutaneous T-cell lymphoma (ATL mimic), and other myeloproliferative disorders.
5.2 Viral vs. Autoimmune Differentiation¶
HTLV-1-associated HAM shows CNS inflammation with viral antigens, while autoimmune disorders lack viral markers.
6. INVESTIGATIONS & DIAGNOSIS¶
Diagnosis requires HTLV-1 serology (ELISA/PCR) and CSF analysis for HAM. Flow cytometry identifies CD4+ T-cell abnormalities. Molecular testing confirms proviral integration. Imaging (MRI) detects CNS lesions in HAM.
6.1 Diagnostic Criteria¶
HTLV-1 seropositivity, CD4+ T-cell abnormalities, and clinical features (skin lesions, CNS involvement). HAM requires CSF analysis and MRI findings.
6.2 Laboratory Tests¶
Serology (ELISA), PCR for viral load, flow cytometry for T-cell abnormalities, and CSF analysis for HAM.
7. MANAGEMENT & TREATMENT¶
Treatment includes chemotherapy (CHOP, EPOCH), interferon, and stem cell transplantation. Antiretroviral therapy (e.g., zidovudine) may reduce viral load. Targeted therapies (e.g., mogamulizumab) and supportive care (fluid management, infection control) are critical.
7.1 Chemotherapy Regimens¶
CHOP, EPOCH, or hyper-CVAD for aggressive ATL. Smoldering ATL may require active monitoring. Allogeneic HSCT is considered for eligible patients.
7.2 Antiretroviral Therapy¶
Zidovudine (AZT) may reduce viral replication. Interferon α combined with AZT improves survival in some cases.
8. PROGNOSIS & COMPLICATIONS¶
ATL has a poor prognosis (median survival 6 months for acute form). HAM is chronic but less lethal. Complications include opportunistic infections, bone marrow failure, and secondary malignancies from gene therapy.
9. SPECIAL CONSIDERATIONS¶
Pregnancy: Avoid breastfeeding in HTLV-1-infected mothers. Gene therapy risks include insertional mutagenesis and secondary malignancies. HIV/HTLV-1 co-infection requires tailored antiretroviral strategies.
10. KEY POINTS & CLINICAL PEARLS¶
Retroviruses integrate into host genomes, driving oncogenesis or immune dysfunction. HTLV-1 is endemic in specific regions with distinct clinical manifestations (ATL vs. HAM). Early diagnosis and targeted therapies improve outcomes, but no cure exists for established infections.